weed 5 cbd craze sanjay gupta cnn special report_00001924.jpg
CNN
weed 5 cbd craze sanjay gupta cnn special report_00001924.jpg
Now playing
02:02
Weed 5: The CBD Craze
Fox News/Twitter
Now playing
01:33
ADL wants Fox News to fire Tucker Carlson over racist comments
CNN
Now playing
02:36
The truth behind Covid-19 vaccines for sale on the dark web
Now playing
04:22
Levi's CEO has message for Mitch McConnell
Now playing
01:54
'You think I'm racist': Former Fox News host storms off camera
Korie Robertson and Willie Robertson of the reality series "Duck Dynasty" attend the Capitol File 58th Presidential Inauguration Reception at Fiola Mare on January 19, 2017 in Washington, DC.
Paul Morigi/Getty Images
Korie Robertson and Willie Robertson of the reality series "Duck Dynasty" attend the Capitol File 58th Presidential Inauguration Reception at Fiola Mare on January 19, 2017 in Washington, DC.
Now playing
01:46
'Duck Dynasty' stars discuss raising biracial son on new show
FOX/"The Masked Singer"
Now playing
01:24
Nick Cannon makes big splash in 'Masked Singer' return
The Drew Barrymore Show/YouTube
Now playing
01:26
'Mom' star speaks out about not having kids in real life
Heinz ketchup packets are shown in New York on Monday, August 22, 2005. H.J. Heinz Co., the world's biggest ketchup maker, said first-quarter profit fell 19 percent on expenses to cut jobs and sell businesses.  (Photo by Andrew Harrer/Bloomberg via Getty Images)
Andrew Harrer/Bloomberg/Getty Images
Heinz ketchup packets are shown in New York on Monday, August 22, 2005. H.J. Heinz Co., the world's biggest ketchup maker, said first-quarter profit fell 19 percent on expenses to cut jobs and sell businesses. (Photo by Andrew Harrer/Bloomberg via Getty Images)
Now playing
01:53
Restaurants face a nationwide ketchup packet shortage
Camerota Berman both
CNN
Camerota Berman both
Now playing
02:33
CNN anchor Alisyn Camerota gets surprise tribute from co-anchor
Citigroup Chairman Richard Parsons delivers remarks on the US economy at the New York State Bar Association meetings in New York, January 28, 2009. Troubled US banking giant Citigroup last week named Parsons as its new chairman, the longtime top executive at media giant Time Warner, to steer it through its most challenging period.  AFP PHOTO / Emmanuel Dunand (Photo credit should read EMMANUEL DUNAND/AFP via Getty Images)
EMMANUEL DUNAND/AFP/AFP via Getty Images
Citigroup Chairman Richard Parsons delivers remarks on the US economy at the New York State Bar Association meetings in New York, January 28, 2009. Troubled US banking giant Citigroup last week named Parsons as its new chairman, the longtime top executive at media giant Time Warner, to steer it through its most challenging period. AFP PHOTO / Emmanuel Dunand (Photo credit should read EMMANUEL DUNAND/AFP via Getty Images)
Now playing
02:47
Dick Parsons: Georgia law is a bald-faced attempt to suppress Black vote
Courtesy of Warner Bros. Picture
Now playing
02:54
'Godzilla vs. Kong' is a pandemic box office hit
Now playing
01:30
5 ways to cut your plastic waste
CNN/Getty Images
Now playing
04:40
Stelter: After elevating Gaetz, Fox News barely covering scandal
NASA/Goddard/University of Arizona
Now playing
01:08
See NASA spacecraft successfully land on an asteroid
Now playing
06:51
Alisyn Camerota's kids wish her good luck in new role on CNN

Programming note: Watch “Weed 5: The CBD Craze,” hosted by Dr. Sanjay Gupta, Sunday at 8 p.m. ET/PT on CNN.

(CNN) —  

Tucked away in the quiet English countryside on more than 47 acres, GW Pharmaceuticals is doing something no other drug company can do: produce the only cannabis-based medication ever approved by the US Food and Drug Administration.

That drug, a treatment for two rare types of epilepsy, inspired researchers to consider what other conditions cannabis might help. A new clinical trial at Montefiore Medical Center in New York will examine the effect of a cannabis compound called cannabidivarin, known as CBDV, on irritability and repetitive behaviors in children with autism spectrum disorder. CBDV is a non-psychoactive chemical compound and does not cause a “high.”

CNN Chief Medical Correspondent Dr. Sanjay Gupta was given exclusive access to the Montefiore study and GW Pharmaceuticals, the British biopharmaceutical company that grows the cannabis used in the trials.

Gupta got an exclusive look at one of GW’s cannabis greenhouses while reporting for “Weed 5: The CBD Craze.” In a grow house that spans 47 acres– roughly 42 football fields – GW is precisely breeding consistent strains of the cannabis plant for medicine. It’s a process that has been enormously difficult to develop and master, according to the company’s head of manufacturing, David Cooper. In a rare tour of GW’s extraction facility, Cooper showed Gupta how GW’s specialized strains of cannabis become medicine for tens of thousands of patients.

“The company’s been in existence for 20 years. Epidiolex was launched towards the end of last year. So I think that journey’s quite a long journey,” Cooper told Gupta.

In 2018, the FDA approved Epidiolex, the first ever cannabis-based oral medication for the treatment of two rare and severe seizure disorders. Clinical trials showed it decreased seizure activity by an average of 45% to 50% in patients with Dravet syndrome, a rare and severe form of childhood-onset epilepsy. The medicine is comprised of cannabidiol, or CBD, a compound extracted from the marijuana plant.

The success of Epidiolex in treating epilepsy motivated the GW to develop a cannabis-based drug for another neurological disorder which, like severe epilepsy, has few treatment options: autism. Turns out, the two disorders share many similar behavioral symptoms.

“When you look at these – loss of cognitive function, poor socializing skills, poor language skills – what you’re looking at is a phenotype very similar to autism,” GW founder Dr. Geoffrey Guy told Gupta during a rare tour greenhouse tour. “In my mind, epilepsy and autism-type presentations are on the same continuum.”

GW’s CBDV is shipped from the UK to Dr. Eric Hollander, director of the Autism and Obsessive Compulsive Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.

Hollander believes the cannabis extract holds hope for treating autism symptoms based on the success it’s had reducing seizure activity.

“There’s some abnormal electrical activity even though they don’t have seizures, for example,” Hollander told Gupta. “And we had previously shown that when we give anticonvulsants that decrease the electrical activity, or the spikes, some of the disruptive behaviors, or the irritability, actually get better.

“And that was one of our thoughts, why this CBDV could be helpful,” Hollander said. “Because if it helps with epilepsy and it helps in terms of decreasing the spike activity, we might also get improvement in the some of the aggression, or the self-injury, or the temper tantrums.”

Hollander is leading the clinical trial. With 30 years of experience in autism spectrum disorder research, Hollander also believes autism and epilepsy could have similar underlying causes.

No cure currently exists for autism. Hollander focuses on treating the associated symptoms and believes CBDV could be a breakthrough in remedying behaviors typically associated with the disorder.

“In some of the animal models that are similar to autism, it was found that CBDV had important effects on social functioning, on decreasing seizures, on increasing cognitive function, and in reducing compulsive or repetitive behavior,” Hollander said. “So for that reason, we wanted to apply that to autism.”

Some autism experts remain cautiously optimistic about cannabis-based medicines treating autism behaviors. Dr. Alexander Kolevzon, clinical director of the Seaver Autism Center at Mount Sinai, is not involved in the Montefiore research but is encouraged by initial reports on CBD-based cannabis medicine. Kolevzon believes cannabis compounds show enough promise to warrant further study but cautioned that the variation and range in the autism spectrum makes it an especially challenging disorder to treat.

“CBD may be helpful for only a subset of people and it may benefit different people in different ways. The challenge is to figure out which patients are likely to respond, and which symptoms are most likely to improve,” Kolevzon told CNN in an email.

Similar in chemistry and benefits to CBD found in marijuana, the CBDV compound Montefiore is studying does not cause intoxication. Launched in April, the clinical trial aims to follow 100 participants ages 5-18 for 12 weeks of treatments through June 2021. It’s estimated the study results will be finalized in September 2021.

For many scientists, Montefiore’s study is an encouraging start, but more research must be done before conclusions are reached.

“The field of autism has a long history of enthusiasm for many treatments based on small pilot studies and anecdotal accounts,” Kolevzon said. However, often when these treatments are tested rigorously in larger studies, the benefits are not significantly different than that of placebo.”

Michael Morrier is the program director of Child Behavioral Interventions at the Emory Autism Center in Atlanta. He is not involved in the Montefiore study but is hopeful that patients and families will continue to focus on autism behavioral therapies in the absence of definitive data on cannabis medicines.

“Anything that’s new that can be something to help a family or an individual to really be a meaningful member of their home, community, school and society is going to be helpful,” Morrier said. “I would just caution that people don’t just jump on the bandwagon and say, ‘This is a cure all, let’s do it,’ because we really don’t know what are the characteristics it works for, what are the behaviors it works for.”

Hollander is hoping the research happening at Montefiore could provide these answers, and in doing so help patients like 14-year-old Carlos Rodriguez. While waiting for his appointment at the hospital, Carlos is playing on his iPhone and wearing a baggy sweatshirt. But it’s 95 degrees, and he’s wearing that sweatshirt because he can’t stand how the air feels on his skin – one of the manifestations of his autism symptoms.

Carlos was diagnosed on the autism spectrum at 4 years old. He has difficulty adapting to changes in his routine and can be triggered into angry tantrums by loud noises and crowds. After eight years of different medications to try regulating his behavior, Carlos and his mother Maribel Gonzalez are looking for better options to treat his symptoms.

Gupta was there for Carlos’ intake and first dose in the study. Carlos said he wanted to join the study to better understand his own autism and help others struggling with it.

“If I don’t have to worry about, like, getting angry or, like, certain schedule being broken … I’d be pretty happy about that,” he told Gupta.

The study is double-blind; neither the participants nor the doctors know if Carlos is taking the CBDV or a placebo. But Carlos and Maribel are hopeful.

Get CNN Health's weekly newsletter

Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.

“He just said, ‘I hope it works, mom.’ That’s all he said. He said, ‘I hope it works,’ ” Maribel told Gupta after watching her son take the first dose. “I was just like, let’s see. In my head, I’m like, let’s see how this goes. I mean, hopeful. Just hopeful. Really hopeful.”

“I’m trying to find something that’s going to help my child,” she said. “Because, at the end of the day, even though he may have these disabilities, I still want my child to be somebody, do something in life. And if there’s something out there that can help him reach that goal, I’ll be in line.”